First U.S.-Based Canine Cancer Registry, Founded by Jaguar Health, to Join International Consortium of Canine Cancer Registries
SAN FRANCISCO, CA / ACCESSWIRE / June 8, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar") today announced that it and the cosponsors of the Take C.H.A.R.G.E Canine Cancer Registry (Canine Health And ReGistry Exchange), joined by their canine friends, leading veterinary oncologists, and child health advocates at a briefing on Capitol Hill for legislative staff, called for increased support to continue the expansion of Take C.H.A.R.G.E., the first and only U.S. canine cancer registry, and to drive awareness and increase funding for comparative oncology research, which focuses on naturally occurring cancer in dogs as models for both canine and human cancer research.
"The science of comparative oncology and the ability to track naturally occurring cancers in the U.S. hold great promise for finding treatments and potential cures for a range of cancers that affect humans and our canine cousins," said Lisa Conte, President and CEO of Jaguar and founder of the Take C.H.A.R.G.E. Canine Cancer Registry. "Our Take C.H.A.R.G.E. team is eager to build support for public-private partnerships that will allow us to more easily track and code canine cancer data, and to make that valuable data easily available to human cancer researchers so that one day we can find a cure for this deadly disease."
Jaguar Health's Take C.H.A.R.G.E. is a first-of-its-kind national canine cancer registry compiling incidence and prevalence data to help guide canine cancer diagnosis and treatment. The registry catalogs key data points to know cancer's impact by breed, type, age, gender, and location. The Take C.H.A.R.G.E Registry is cosponsored by Jaguar Animal Health; TogoRun, a global health communications agency; and Ivee, an animal health software company. The registry launched in May 2022 with a retrospective review of more than 35,000 anonymous canine patient records, with 830 cancer patient records uploaded into a secure, customized database, and now contains 1,160 confirmed cancer diagnoses, representing a 40% increase to date. Take C.H.A.R.G.E has collected an additional 232,000 canine patient records from which confirmed cancer diagnoses will be added to the registry.
Take C.H.A.R.G.E. Scientific Advisory Board Co-Chair, Craig Clifford, DVM, MS, DACVIM (Oncology) joined Carol Robertson-Plouch, DVM, a member of the Board of Directors for the Canines-N-Kids Foundation, Chiara Palmieri, DVM, PhD, Diplomate ECVP, Co-Coordinator, Global Initiative for Veterinary Cancer Surveillance (GIVCS), and Amy LeBlanc, DVM, Diplomate ACVIM (Oncology), Director, Comparative Oncology Program at the National Cancer Institute, to brief congressional staff on the importance of incorporating a universal canine cancer coding system to registries and the applications they provide for advancing human cancer research.
Given its success to date, Take C.H.A.R.G.E. has been invited to join the Global Initiative for Veterinary Cancer Surveillance - an international consortium of canine cancer registries with a mission to: 1) promote international collaborations in animal cancer surveillance and research; 2) create a consensus on and foster the establishment of standardized methods for animal cancer coding and reporting; 3) provide an inclusive channel to exchange information between veterinary cancer registries.
"The Take C.H.A.R.G.E. registry has already compiled a significant amount of valuable data to help advance comparative oncology research and we are excited to welcome them into our international consortium of canine cancer registries," said Maria Lucia Zaidan Dagli, DVM, MS, PhD, President, Global Initiative for Veterinary Cancer Surveillance. "The Take C.H.A.R.G.E. team will be a vital partner in our effort to identify and track changes in cancer burdens between human populations and canines over time and around the world."
Associated Press Event Photos available as of approximately 4:00pm on June 8th:
Take C.H.A.R.G.E. Registry Advancing Cancer Research for Canines and Children
Take C.H.A.R.G.E. Scientific Advisory Board (SAB)
The Take C.H.A.R.G.E. SAB includes 8 leading US veterinarians specializing in canine oncology and surgery. One of the board's activities is driving adoption of a consistent canine cancer diagnostic coding system in the U.S. and supporting the goals of the National Institutes of Health/National Cancer Institute Comparative Oncology Program.
The Take C.H.A.R.G.E. SAB members include SAB co-chairs Clifford and Theresa (Terry) W. Fossum, DVM, MS, PhD, Diplomate ACVS; as well as Susan Ettinger, DVM, DACVIM (Oncology), also known as Dr Sue Cancer Vet®; Trina Hazzah, DVM, DACVIM (Oncology), CVCH; Chad M. Johannes, DVM, DACVIM (SAIM, Oncology); Doug Thamm, V.M.D., Diplomate ACVIM (Oncology); David Vail, DVM, MS, DACVIM (Oncology); and Rachel Venable, DVM, MS, DACVIM (Oncology).
Take C.H.A.R.G.E. Website
Data from the registry is accessible to the public via an interactive, easy-to-use dashboard on the Take C.H.A.R.G.E. website, with open access for clinical practitioners and academia to all canine cancer medical record data for research purposes. The registry continues to grow as veterinary clinics and pet owners upload medical records of dogs with cancer at no cost to clinics or pet owners. The data is de-identified, anonymized, and protected following General Data Protection Regulation (GDPR) guidelines to ensure participant information privacy.
TogoRun is a woman-owned, award-winning, full-service strategic communications, marketing, and public affairs agency focused on global health and well-being and telling the untold story. Inspired by the 1925 hero sled dog Togo, TogoRun works in partnership with clients committed to advancing innovative solutions that save and improve lives, close health disparity gaps, support a healthier planet, and embrace a vision of equitable abundance. Headquartered in New York, with seasoned teams in Washington, D.C., Los Angeles, and virtually everywhere via a network of global partners in +90 markets, TogoRun specializes in integrated marketing and communications, branding and positioning, advocacy and government affairs, issues and crisis management, and corporate communications. Areas of expertise include pharma/biotech, life sciences, health information technology, medical device, health insurance, hospital, non-profits/associations, medical aesthetics, consumer packaged goods, and beauty. TogoRun is part of the GMJ Global network of companies and a proud signatory of CEO Action for Diversity & Inclusion. The TogoRun Team has collectively been responsible for more than 230 industry awards, including Inc. Magazine's Best Workplaces in 2023 and Best in Business for Marketing in 2022, and donates at least 11% of time each year in pro bono services to non-profits that share our values. Visit us here: www.TogoRun.com. And follow us on Facebook, Instagram, LinkedIn, and, Twitter.
Ivee, a product of Snowcap Innovations Inc, solves the challenging unstructured data problem in the animal healthcare industry. Our mission is to help organizations access and gain value from all of their data assets to develop a deeper understanding of the patient & clinic population to improve quality and outcomes for animal care.
About Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, & Jaguar Animal Health,
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on the development of rare disease indications of crofelemer and expanding crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar Health.
For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com.
Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT: Nicky Diaz
SOURCE: Jaguar Health
View source version on accesswire.com: